SCHEMBL5312930

SCHEMBL5312930

O=C(O)CCCC(=O)c1ccc2c(c1)CCO2

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 8/20 0.61
WNT3A P56704 7/20 0.61
PKM P14618 1/20 0.58
TSHR P16473 1/20 0.58
ALDH1A1 P00352 3/20 0.56
PRKCI P41743 1/20 0.51
TP53 P04637 2/20 0.51
MAPT P10636 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
KLF5 Q13887 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ACHE P22303 1/20 0.51
TAS1R3 Q7RTX0 2/20 0.48
TAS1R1 Q7RTX1 2/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4260152 0.91 PKM (0.70) CTNNB1WNT3APKMTSHRALDH1A1
SCHEMBL4857484 0.84 CTNNB1 (0.56) CTNNB1WNT3APKMTSHRALDH1A1
SCHEMBL5311636 0.84 CTNNB1 (0.53) CTNNB1WNT3APRKCISMN1; SMN2ACHE
SCHEMBL11022828 0.82 HPGD (0.70) CTNNB1WNT3APKMTSHRPRKCI
SCHEMBL15088740 0.82 CTNNB1 (0.60) CTNNB1WNT3APKMTSHRALDH1A1
SCHEMBL14044259 0.80 PRKCI (0.58) CTNNB1WNT3APKMTSHRPRKCI
SCHEMBL1182701 0.79 PRKCI (0.57) CTNNB1WNT3APKMTSHRALDH1A1
SCHEMBL6181845 0.79 PRKCI (0.57) CTNNB1WNT3APKMTSHRPRKCI
SCHEMBL1091802 0.79 ATM (0.69) CTNNB1WNT3APRKCIACHETAS1R3
SCHEMBL9670805 0.78 FFAR4 (0.55) CTNNB1WNT3AALDH1A1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007052831-A1 PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-10 WO disclosed
WO-2007052831-A1 PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-10 WO disclosed
US-20070099986-A1 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-03 US disclosed
US-20070099986-A1 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-03 US disclosed
US-20070099986-A1 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099986-A1 Preventives/remedies for urinary disturbance REN, GLS, ATP6V1B1 CTNNB1 3429/4885WNT3A 3737/4885PKM 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.